Baijin Xia

884 total citations
15 papers, 243 citations indexed

About

Baijin Xia is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Baijin Xia has authored 15 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Infectious Diseases. Recurrent topics in Baijin Xia's work include CAR-T cell therapy research (8 papers), HIV Research and Treatment (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Baijin Xia is often cited by papers focused on CAR-T cell therapy research (8 papers), HIV Research and Treatment (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Baijin Xia collaborates with scholars based in China, United States and Nigeria. Baijin Xia's co-authors include Hui Zhang, Bingfeng Liu, Lijuan Lu, Fan Zou, Wanying Zhang, Yingtong Lin, Yiwen Zhang, Qifei Hu, Jun Liu and Mei Huang and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Virology.

In The Last Decade

Baijin Xia

14 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Baijin Xia China	8	158	91	84	41	34	15	243
Tara S. Abraham United States	5	212 1.3×	58 0.6×	115 1.4×	60 1.5×	45 1.3×	9	311
M Mach Australia	6	144 0.9×	119 1.3×	79 0.9×	20 0.5×	68 2.0×	8	321
J. Joseph Melenhorst United States	5	161 1.0×	63 0.7×	155 1.8×	30 0.7×	80 2.4×	9	374
Dustin Cobb United States	9	99 0.6×	78 0.9×	167 2.0×	18 0.4×	17 0.5×	16	328
Curtis Cai Australia	8	171 1.1×	138 1.5×	128 1.5×	33 0.8×	66 1.9×	14	303
Megan S. McAfee United States	7	200 1.3×	90 1.0×	177 2.1×	22 0.5×	33 1.0×	12	315
Alessia Scarselli Italy	9	108 0.7×	71 0.8×	179 2.1×	37 0.9×	70 2.1×	14	307
Sandra Rosskopf Austria	8	128 0.8×	61 0.7×	168 2.0×	13 0.3×	16 0.5×	10	289
Diana Lim Singapore	10	72 0.5×	182 2.0×	52 0.6×	19 0.5×	22 0.6×	19	331
Sara Bolivar-Wagers United States	8	114 0.7×	45 0.5×	170 2.0×	36 0.9×	31 0.9×	10	250

Countries citing papers authored by Baijin Xia

Since Specialization

Citations

This map shows the geographic impact of Baijin Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baijin Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baijin Xia more than expected).

Fields of papers citing papers by Baijin Xia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baijin Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baijin Xia. The network helps show where Baijin Xia may publish in the future.

Co-authorship network of co-authors of Baijin Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Baijin Xia. A scholar is included among the top collaborators of Baijin Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baijin Xia. Baijin Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Xing, Fan, Xuemei Wang, Jintao Guo, et al.. (2025). Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity. The Journal of Experimental Medicine. 222(11). 1 indexed citations

Zhang, Yucheng, et al.. (2025). Clonal Hematopoiesis of Indeterminate Potential as a Predictor of Colorectal Cancer Risk: Insights from the UK Biobank Cohort. Cancer Epidemiology Biomarkers & Prevention. 34(3). 405–411. 3 indexed citations

Xia, Baijin, Xinmiao Jiang, Jialing Guo, et al.. (2025). Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy. Pharmacological Research. 213. 107628–107628. 4 indexed citations

Cao, Lixue, Yanzhen Chen, Baijin Xia, et al.. (2024). ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis. Journal for ImmunoTherapy of Cancer. 12(11). e010028–e010028. 4 indexed citations

Lin, Keming, Baijin Xia, Xuemei Wang, et al.. (2024). Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology. Journal of Translational Medicine. 22(1). 349–349. 7 indexed citations

Yang, Tao, Ming Yuan, Xinyu Li, et al.. (2024). ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latency. Journal of Virology. 98(8). e0003524–e0003524. 4 indexed citations

Chen, Cancan, Wanying Zhang, Baijin Xia, et al.. (2024). Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation. Journal of Virology. 99(1). e0117324–e0117324.

Chen, Tao, Jieyi Deng, Yongli Zhang, et al.. (2024). The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Molecular Cancer. 23(1). 53–53. 10 indexed citations

Qiao, Yidan, Jie Chen, Xuemei Wang, et al.. (2023). Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Communications. 43(7). 788–807. 36 indexed citations

10.

Xia, Baijin, Keming Lin, Xuemei Wang, et al.. (2023). Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Molecular Therapy — Oncolytics. 30. 86–102. 18 indexed citations

11.

Zhang, Wanying, Mo Zhou, Cancan Chen, et al.. (2022). Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection. mBio. 13(6). e0249622–e0249622. 6 indexed citations

12.

Luo, Yuewen, Fei Yu, Mo Zhou, et al.. (2021). Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors. mBio. 12(1). 22 indexed citations

13.

Zhang, Junsong, Feng Huang, Baijin Xia, et al.. (2021). The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. Signal Transduction and Targeted Therapy. 6(1). 189–189. 26 indexed citations

14.

Zou, Fan, Lijuan Lu, Jun Liu, et al.. (2019). Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nature Communications. 10(1). 4109–4109. 92 indexed citations

15.

Liu, Bingfeng, Wanying Zhang, Liyang Wu, et al.. (2019). Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef–AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells. Frontiers in Immunology. 10. 2151–2151. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact